Brooks Laboratories Ltd
As of 20 Nov 2026, Brooks Laboratories is in Stage 1, the basing phase, now in week 3 (since 2 Nov 2026). It closed at ₹67.20, 37.2% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. More about the company
Pro read
ProBROOKS is basing for 3 weeks, above its 50-day average; it has not started an uptrend yet.
Its relative strength is 16 of 99, below the middle among NSE stocks over the past year. Labs & Life Sciences Services ranks 70 of 106 industries by the strength of its stocks.
Is BROOKS early, or has it already run? Pro answers that for every NSE stock, after every close.
BROOKS among Labs & Life Sciences Services5th of 6 by relative strength
All 6 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | DIVISLAB | Stage 2 · wk 26 | 93 | +21.7% |
| 2 | AARTIPHARM | Stage 2 · wk 13 | 84 | +17.5% |
| 3 | VIMTALABS | Stage 3 · wk 5 | 30 | −4.3% |
| 4 | SYNGENE | Stage 1 · wk 1 | 23 | +20.0% |
| 5 | BROOKS | Stage 1 · wk 3 | 16 | +10.6% |
| 6 | DCAL | Stage 4 · wk 14 | 5 | −18.7% |
Mutual fund holdings
Held by 1 mutual funds in portfolios to October 2026: 1 active funds and 0 index funds and ETFs.
In October, no active fund changed its holding.
All 1 funds and what each did in October
Mutual funds holding BROOKS: the ten largest and the month’s moves →
Brooks Laboratories: quick answers
What stage is Brooks Laboratories in?
As of 20 Nov 2026, Brooks Laboratories (BROOKS) is in Stage 1, the basing phase. It entered Stage 1 on 2 Nov 2026 and is in week 3. What the four stages mean
Is Brooks Laboratories in an uptrend?
Not yet. Brooks Laboratories is in Stage 1, a base that can come before an uptrend. It trades 6.3% above its 200-day average, which is falling.
How far is Brooks Laboratories from its 52-week high?
Brooks Laboratories closed at ₹67.20 on 20 Nov 2026, 37.2% below its 52-week high of ₹107. Its 52-week low is ₹37.11.
How has Brooks Laboratories performed over the past year?
As of 20 Nov 2026, Brooks Laboratories is down 38.8% over the past year and down 16.1% so far in 2026.
Which sector and industry is Brooks Laboratories in?
Brooks Laboratories is in the Labs & Life Sciences Services industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care
About this companyHealth Care· Labs & Life Sciences Services
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.